A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of AZD4041 in Healthy Adult Subjects
Latest Information Update: 30 Nov 2023
At a glance
- Drugs AZD 4041 (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 04 Jul 2022 Status changed from recruiting to completed.
- 29 Mar 2022 Planned number of patients changed from 48 to 36.
- 29 Mar 2022 Planned End Date changed from 20 May 2022 to 27 May 2022.